Evotec (ADR) (EVO)
Combines discovery, development and biologics manufacturing for pharmaceutical and biotechnology partners.
Something off on this page? Send us feedback.
Provides discovery, preclinical development and biologics services through collaborations with pharmaceutical and biotechnology customers. Its two reporting segments pair a shared R&D platform with Just – Evotec Biologics.
Offers drug discovery, preclinical development and manufacturing capabilities through partnerships with pharmaceutical and biotechnology customers. Discovery Services, Development & Manufacturing Services and Cyprotex ADME-Tox Solutions support work from disease understanding through development.
Just – Evotec Biologics adds biologics design, development and manufacturing capabilities, including the J.DESIGN platform. The business expanded through the acquisition of Just Biotherapeutics and complements small-molecule and biologics work across an international site network.
Reporting is organized around Discovery & Preclinical Development and Just – Evotec Biologics. The operating model is being simplified through footprint and capacity optimization, while delivery remains structured around externally partnered research and development programs.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Jul 15, 2026 | H.C. Wainwright | Reiterate | Rating: —Target: $7 | Target: $4 |
| Jul 15, 2026 | Macquarie | Target | Target: — | Target: $2 |
| Jul 14, 2026 | Cowen & Co. | Downgrade | ||
| Jun 29, 2026 | William Blair | Downgrade | Rating: — |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $533.1M · Total debt $544.9M · Total assets $1.80B · Shareholders' equity $762.1M
- Revenue
- $167.0M
- Operating income
- −$59.5M
- Net income
- −$54.3M
Reported in EUR, converted at the latest exchange rate
No dividends on record.
| Institutions | 0.91% | 3.24M ADS | |
|---|---|---|---|
| 35 holders · as of Jun 30, 2026 | |||
| Other | 99.09% | 352.00M ADS | |
| remainder | |||
355.24M ADS (1 ADS = 1 ordinary shares) as of Aug 31, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
The share count is from the company's Dec 2022 annual report; nothing newer is on file here.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
DCF Advisers, LLCInstitution | 0.30% | 1.08M ADS | as of Jun 30, 2026 |
WCM Investment Management, LLCInstitution | 0.19% | 671,884 ADS | as of Jun 30, 2026 |
Abc Arbitrage SAInstitution | 0.10% | 371,936 ADS | as of Jun 30, 2026 |
Optiver Holding B.V.Institution | 0.09% | 322,153 ADS | as of Jun 30, 2026 |
Morgan StanleyInstitution | 0.06% | 205,763 ADS | as of Jun 30, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
- Charles River Laboratories
Broad preclinical CRO and biologics-services overlap
- Recursion Pharmaceuticals
AI-native drug-discovery platform rival
- Schrödinger
Physics-based computational molecular-discovery rival
- AbCellera Biologics
Technology platform for antibody-medicine discovery
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Evotec (ADR) | $1.58 | +0.64% | $547.1M | — | — | 0.7 | −17.3% |
| Charles River Laboratories | $285.11 | +0.05% | $13.44B | — | 23.1 | 3.4 | −2.7% |
| Recursion Pharmaceuticals | $4.05 | 0.00% | $2.08B | — | — | 38.0 | −61.8% |
| Schrödinger | $31.00 | +0.98% | $2.26B | — | — | 8.7 | +7.5% |
| AbCellera Biologics | $12.71 | +0.53% | $3.87B | — | — | 58.4 | −76.3% |
| Median | — | 23.1 | 23.3 | −32.2% |